Healing & RecoveryLimited ResearchResearch OnlyS

BPC-157

Pentadecapeptide BPC 157 · Upregulates VEGF, EGF, and growth factor signaling; promotes angiogenesis; modulates nitric oxide (NO) synthase; activates FAK-paxillin and JAK-STAT pathways

Last reviewed . First published . By the PeptIQ team.

Educational and observational reference only. Not medical advice. Community charts use live PeptIQ self-reports.

Studies cited
14
Research grade
S
Experience
99

Overall check-ins

Activity
70

Trackers & reports

Typical Dose

250–500 mcg daily

Route

Injectable

Cycle

4–12 week cycles

Storage

2–8°C Refrigerated

What is BPC-157?

BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a gastric juice protein, researched extensively for accelerating tissue healing, gut repair, and tendon recovery. Animal studies demonstrate dose-dependent healing of tendons, ligaments, bones, muscles, and intestinal tissue, along with anti-inflammatory and angiogenic effects. Not FDA-approved; placed on the FDA's 503A prohibited bulk substances list in 2023.

Mechanism of Action

Upregulates VEGF, EGF, and growth factor signaling; promotes angiogenesis; modulates nitric oxide (NO) synthase; activates FAK-paxillin and JAK-STAT pathways

Target: VEGF receptors, NO pathway, FAK-paxillin

Research / educational reference. Educational research index only — not medical advice. Literature maturity is not a verdict on whether a compound works in people. Community reports are not evidence of efficacy.

Evidence at a glance

Derived · maturity-1.0

Human efficacy is unproven unless an approved label or completed published efficacy program says otherwise. Counts reflect indexed literature volume/kind — never a verdict on effect.

Literature maturity

emerging 38/100

PubMed hits

223

CT.gov trials

4

Strong-human apps

0

Sample papers

8

Sample articles by era

  • pre-20182
  • 2018-20204
  • 2021-20236
  • 2024-20267

Application grades (curated)

  • Human-grade apps0
  • Animal / in-vitro2
  • Mechanistic0

Does literature support studied applications?

Grades reflect cited literature posture — not a treatment recommendation. Community notes are never efficacy evidence.

ApplicationCited evidenceGradeCommunity
Soft-tissue healing (preclinical)

Multiple rodent studies report accelerated tendon/ligament/muscle healing signals.

Animal / in-vitroCommunity reports vary; not evidence of efficacy.
Gastrointestinal mucosal protection (preclinical)

Animal models suggest cytoprotective effects in GI injury contexts.

Animal / in-vitroCommunity reports vary; not evidence of efficacy.
Human clinical efficacy

Robust completed human efficacy RCTs are lacking for common wellness claims.

Anecdotal onlyCommunity reports vary; not evidence of efficacy.

Pharmacology

Mechanism of action

  • •Upregulates VEGF, EGF, and growth factor signaling; promotes angiogenesis; modulates nitric oxide (NO) synthase; activates FAK-paxillin and JAK-STAT pathways
  • •Primary target framing: VEGF receptors, NO pathway, FAK-paxillin

Half-life

~4 hours

Identity & chemistry

CAS
137525-51-0
Formula
C62H98N16O22
Molar mass
1419.5 Da
InChIKey
HEEWEZGQMLZMFE-RKGINYAYSA-N

Identity cross-checked with PubChem where available. Compass HTML used only as a bootstrap checklist — not republished as product copy.

Storage & stability

Lyophilized
2–8°C; lyophilized typical shelf 24+ months
Reconstituted
2–8°C; in-use window often 28–45 days (product-dependent)
Tell-tale degradation
  • !Cloudiness, clumping, or particles after mixing
  • !Discoloration versus the expected clear/colorless (or labeled) solution
  • !Failed or incomplete reconstitution of lyophilized cake

Educational estimates. Prefer product labeling and peptide shelf-life tool.

Lab handling posture

Research / educational handling notes only. Not a substitute for an SDS.

  • •Use PPE appropriate for peptide powder/solution handling
  • •Avoid inhalation of lyophilized powder; handle spills per institutional policy
  • •Do not present research materials as medicines

Sample indexed literature

Research Indications

Tissue RepairMost Effective

Demonstrated acceleration of wound healing and soft tissue repair in research

Gut HealthEffective

Research shows beneficial effects on intestinal lining and GI function

Joint SupportEffective

Associated with reduced joint inflammation and improved mobility

Muscle RecoveryModerate

May support faster recovery from muscle strains and exercise stress

Research Protocols

These are commonly discussed research protocols — not medical advice. Consult a healthcare provider before use.

GoalDoseFrequencyRoute
Starting Dose250 mcg dailyOnce dailySubcutaneous injection
Standard Dose500 mcg dailyOnce dailySubcutaneous injection
Split Dosing250 mcgTwice dailySubcutaneous injection
Maintenance / Gut Protocol250 mcg dailyOnce daily (AM fasted)Oral (research only)

Peptide & Drug Interactions

Always consult your healthcare provider before combining with other compounds. Use our Interaction Checker for reference.

TB-500 / BPC-157 (stack)Compatible
NSAIDs (Ibuprofen, Naproxen)Caution
CorticosteroidsCaution
AnticoagulantsMonitor
GH SecretagoguesCompatible
NAD+Compatible

How to Reconstitute & Inject

Use bacteriostatic (BAC) water only. Avoid saline — may cause precipitation. Refrigerate and use within 28 days.

  1. 1

    Remove BPC-157 vial from refrigeration and allow to reach room temperature (15–20 minutes)

  2. 2

    Clean vial top with alcohol swab and allow to air dry completely

  3. 3

    Using a sterile syringe, draw the calculated volume of bacteriostatic water (BAC water)

  4. 4

    Inject BAC water slowly down the side of the vial — do not aim directly at the powder

  5. 5

    Gently swirl in circular motions — DO NOT shake vigorously as this degrades the peptide

  6. 6

    Allow 2–3 minutes for full dissolution — solution should be clear and colorless

  7. 7

    Draw calculated dose into an insulin syringe for subcutaneous injection

  8. 8

    Inject into abdomen, thigh, or upper arm. Rotate injection sites to prevent lipodystrophy

  9. 9

    Store reconstituted solution refrigerated (2–8°C) and use within 28 days

What to Expect

Week 1–2

Initial anti-inflammatory effects begin. Reduced pain and swelling in target area.

Week 2–4

Improved tissue mobility and reduced discomfort. Early healing acceleration.

Week 4–8

Significant recovery milestones. Stronger tissue repair and functional improvement.

Week 8–12

Near-complete healing in many cases. Improved strength and tissue integrity.

Side Effects & Safety

  • Generally well-tolerated in research settings
  • Mild nausea with higher doses
  • Injection site redness or discomfort
  • Rare: Dizziness or lightheadedness
  • Potential effect on blood pressure (monitor if hypertensive)

BPC-157 is not FDA-approved and cannot be prepared by 503A compounding pharmacies. PeptIQ does not sell peptides or list vendors. Talk with a licensed clinician.

FDA Status & Regulatory Info

Research Only

BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a gastric juice protein, researched extensively for accelerating tissue healing, gut repair, and tendon recovery. Animal studies demonstrate dose-dependent healing of tendons, ligaments, bones, muscles, and intestinal tissue, along with anti-inflammatory and angiogenic effects. Not FDA-approved; placed on the FDA's 503A prohibited bulk substances list in 2023.

Rx Required: No
503A Ban: Yes
Telehealth: N/A
Full FDA Status Tracker

Frequently Asked Questions

Community-reported data

The information below reflects self-reported experiences from PeptIQ app users. It is not clinical evidence and should not replace professional medical advice.

What 128 users report

Observational self-reports from live PeptIQ aggregates. Not clinical outcomes.

128 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 98% · Mixed 2% · Unfavorable overall 0%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Recovery
247
Energy
2
Sleep
1

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Nausea
5
Inflammation
1

Self-reported dose per injection

Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg

Reports span 0 to ≥ 5 mg (open-ended top bucket)

0–0.01 mg
2
0.025–0.05 mg
1
0.1–0.2 mg
3
0.2–0.4 mg
138
0.4–0.6 mg
94
0.6–1 mg
5
1–2 mg
1
3–5 mg
1
5+ mg
1

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

How repeat users are trending

Among repeat reporters, 94% said they felt similar to their last entry, 6% more positive, and 0% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 50 days · Based on 47 repeat reporters

Share Your Experience

Rate BPC-157 in the PeptIQ app and help the community make informed decisions.

Research References (10)

Cited PubMed, trial registry, and label sources for education only. We do not control third-party content.

  1. PubMed

    Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract

    Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2018

    Source
    Wiki study page →
  2. PubMed

    Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts

    Chang CH, Tsai WC, Lin MS, et al. Molecules. 2019

    Source
    Wiki study page →
  3. PubMed

    BPC 157 and its role in accelerating wound healing

    Vukojevic J, Siroglavic M, Kasnik K, et al. Int J Mol Sci. 2022

    Source
    Wiki study page →
  4. ClinicalTrials.gov

    BPC-157 studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  5. PubMed

    BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing

    Seiwerth S, Rucman R, Turkovic B, et al. Current pharmaceutical design. 2018

    Source
    Wiki study page →
  6. PubMed

    Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions

    Ilic S, Drmic D, Franjic S, et al. Life sciences. 2011

    Source
    Wiki study page →
  7. PubMed

    Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain

    Lee E, Padgett B. Altern Ther Health Med. 2021

    Source
    Wiki study page →
  8. PubMed

    From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management

    Yuan C, Demers A, Silva-Ortiz V, et al. Int J Mol Sci. 2026

    Source
    Wiki study page →
  9. PubMed

    Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians

    Mayfield CK, Bolia IK, Feingold CL, et al. Am J Sports Med. 2026

    Source
    Wiki study page →
  10. PubMed

    Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions

    Rahman OF, Lee SJ, Seeds WA. JAAOS Glob Res Rev. 2026

    Source
    Wiki study page →

Wiki tools

Observational indexes and compare views for BPC-157.

Educational information only

This page is for educational reference. It is not medical or legal advice. PeptIQ does not sell peptides or list vendors. Consult the FDA and a licensed healthcare professional for current regulations and individualized guidance.

PeptIQ app

Log your BPC-157 protocol in PeptIQ

Turn this BPC-157 guide into a living protocol — doses, vials, and history in one place.

Track BPC-157Open web app

iOS, Android, and web

Research supplier

BPC-157 listings are for laboratory / research use only — not for human consumption.

Research use only. Partner link. PeptIQ may earn a referral fee. Not medical advice.

Ask PeptIQ

Two taps on our guided quiz, then keep going in iMessage with sources — not Instagram screenshots.

Start the quizOr try Peptide X Quiz →

Quick Facts

Half-Life
~4 hours
Target
VEGF receptors, NO pathway, FAK-paxillin
Route
Injectable
Availability
Research only
Rx Required
No
503A Ban
Yes
Browse peptide education

Talk with a clinician

PeptIQ is education only. We do not sell peptides or list vendors. Discuss BPC-157 with a licensed healthcare provider — not medical advice, not a prescription.

Download PeptIQ

Wiki tools

Observational indexes and compare views for BPC-157.